Centre for Commercialization of Regenerative Medicine

Centre for Commercialization of Regenerative Medicine

CCRM, based in Montreal with offices in Vancouver and Toronto, operates as a non-profit catalyst for regenerative medicine commercialization. Michael May serves as President and CEO, overseeing an organization that brings together academic researchers, industry partners, and government stakeholders to advance cell and gene therapies. The entity lacks a publicly disclosed founding year but positions itself as a central coordinator in Canada's advanced therapies ecosystem. CCRM employs a collaborative model, developing and scaling companies at the interface of academia and industry. Its strategy covers regenerative medicine technologies, addressing key bottlenecks in commercialization through translational platforms. The firm works across asset classes, including direct company creation and infrastructure development — exemplified by OmniaBio's GMP-compliant manufacturing facility and CCVP's cell and gene therapy value platform. Geographic focus is primarily Canadian, with a national footprint across Quebec, British Columbia, and Ontario. In 2021, CCRM and CellCAN launched the Canadian Advanced Therapies Training Institute (CATTI) to address workforce shortages in biomanufacturing. CATTI, led by CEO Vanessa Laflamme and chaired by William Brock, offers training programs. The organization also operates the CCRM Foundation for strategic philanthropy in advanced therapies. These initiatives complement CCRM's industry network, which engages stakeholders across the regenerative medicine value chain. CCRM's structural differentiator is its hybrid model — a non-profit that functions as a company-builder, translational infrastructure provider, and workforce trainer, all focused on one therapeutic modality. This structure allows it to pool public and private resources for pre-commercial-stage technologies, a role normally split across venture capital, academic tech transfer, and government labs.